Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.


Main focus: Next generation allogeneic CAR-T cell therapies

Company stage: Clinical

Diseases: acute myeloid leukaemia, B-cell acute lymphoblastic leukaemia (B-ALL), multiple myeloma, Non-Hodgkin's lymphoma

Genome editing technology: TALEN

Funding stage: Public (NASDAQ:CLLS)

Location: Paris, France and New York, USA



Partners: Allogene Therapeutics, Servier Biopharmaceuticals, Iovance Biotherapeutics, Cytovia Therapeutics

Cellectis develops next generation allogeneic CAR-T cell therapies using its proprietary Transcription activator-like effector nuclease (TALEN) technology. The company has multiple clinical assets currently in Phase 1/2 dose escalation and dose expansion studies. The initial focus is on different types of haematological cancers, such as Non-Hodgkin's lymphoma and leukaemia. The company has licensed the TALEN technology to multiple other companies working with cellular therapies.


HashtagCellectis S.A.

Company: Cellectis
Search CRISPR Medicine